Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Other |
Cost-effectiveness ratios of i-CCM and Pro-CCM |
Cost effectiveness ratios will be presented from three perspectives (i) intervention costs alone, (ii) potential costs/savings to health providers (MoH), (iii) potential societal costs/savings, which includes both health providers and households. Costs to the health care providers and households associated with Pro-CCM and i-CCM will be collected as part of routine trial data collection where possible, with supplementary cost and resource use data collected when necessary. In addition, the economic costs to the health system will be based on detailed cost data from Community Health Workers and health facilities. A standardised costing template will be used in all the sites to record resource use associated with personnel, materials and supplies, equipment, transport, utilities and buildings. Effects will be based on trial outcomes. Specifically, economic evaluation will explore cost of Pro-CCM per disability-adjusted life year saved among children aged 0-59 months. |
36 months |
|
Other |
Equity implications of i-CCM and Pro-CCM |
Data on the socio-economic characteristics of study participants will be collected as part of the survey tool, and will include questions that make up the DHS Wealth Index for Mali in order to measure household poverty/wealth. The percentage of children receiving treatment within 24 hours of symptom onset and the survival rate of children 0-59 months will be analysed stratified across wealth quintiles in each trial arm. |
36 months |
|
Other |
Affordability of Pro-CCM at scale |
Whether a Pro-CCM program would be affordable to the Ministry of Health will be explored. A simple model forecasting the costs of introducing and sustaining Pro-CCM will be developed and this will run using various 'delivery' (supply) and 'uptake' (demand) scenarios. This model will help to inform decision makers about the affordability of implementing Pro-CCM in their setting. |
36 months |
|
Primary |
Difference in the under-five child mortality rate between the two study arms |
To assess the effectiveness of ProCCM compared to a passive iCCM intervention, we will compare the three-year under-five mortality rate in treatment versus control clusters collected prospectively in the 12-, 24- and 36-month follow-up surveys.
We will calculate under-five mortality rate as the number of deaths among children under five years of age per 1,000 person-years of exposure to the risk of mortality for each cluster over the 36-month trial period. |
36 months |
|
Secondary |
Difference in the infant mortality rate between the two study arms |
Infant mortality rate (IMR) is the number of deaths per 1,000 live births among infants aged 0-11 months. We will calculate the IMR over the 36-month trial period. |
36 months |
|
Secondary |
Difference in the newborn mortality rate between the two study arms |
Newborn mortality rate (NMR) is the number of deaths per 1,000 live births among newborns aged 0-28 days. We will calculate the NMR over the 36-month trial period. |
36 months |
|
Secondary |
Difference in the maternal mortality rate between the two study arms |
Maternal mortality ratio (MMR) is the number of deaths among women while pregnant or within 42 days of delivery or termination per 100,000 live births. We calculate the MMR over the 36-month trial period. |
36 months |
|
Secondary |
Difference in the percentage of women receiving 3 or more doses of SP during their last pregnancy between the two study arms |
We will calculate the percentage of women receiving 3 or more doses of Sulfadoxine-Pyrimethamine (SP) during their last pregnancy in the context of Intermittent Preventive Treatment (IPTp) over the 36-month trial period. |
36 months |
|
Secondary |
Difference in the percentage of under-five children with fever in the prior two weeks who receive testing and/or effective treatment for malaria within 24 hours of symptom onset between the two study arms |
The percentage of under-five children with fever in the prior two weeks who receive testing and/or effective treatment for malaria within 24 hours of symptom onset: Among all children who report fever within the two weeks prior to the endline survey (36 months), proportion who report receipt of a malaria rapid diagnostic test (mRDT) and, if the mRDT positive, artemisinin-based combination therapy (arthemeter-lumefantrine) over the 36-month trial period. |
36 months |
|
Secondary |
Difference in the percentage of children under five with diarrhea in the past two weeks who received zinc and oral rehydration therapy within 24 hours of symptom onset between the two study arms |
We will calculate percentage of children under five with diarrhoea in the past two weeks who received zinc and oral rehydration therapy within 24 hours of symptom onset over the 36-month trial period. |
36 months |
|
Secondary |
Difference in the percentage of children with acute respiratory illness evaluated by a qualified provider within 24 hours of symptom onset between the two study arms |
We will calculate the percentage of children with acute respiratory illness (ARI) evaluated by a qualified provider within 24 hours of symptom onset. Among all children who report ARI within the two weeks prior to the endline survey (36 months), proportion who attended a skilled provider within 24 hours of onset of ARI. Skilled providers include CHWs, doctors, nurses, or other providers based at the health center care. |
36 months |
|
Secondary |
Difference in the percentage of the population accessing CHW or health centre care per month between the two study arms |
We will calculate the percentage of the population accessing CHW or health centre care per month over the 36-month trial period. |
36 months |
|
Secondary |
Difference in the percentage of the population visiting the health centre per month between the two study arms |
We will calculate the percentage of the population visiting the health centre per month over the 36-month trial period. |
36 months |
|
Secondary |
Difference in the percentage of population receiving CHW health care per month between the two study arms |
We will calculate the percentage of population receiving CHW health care per month over the 36-month trial period. |
36 months |
|
Secondary |
Difference in the percentage of the health care seeking population who receive CHW care per month between the two study arms |
We will calculate the percentage of the health care seeking population who receive CHW care per month over the 36-month trial period. |
36 months |
|
Secondary |
Difference in the number of curative consultations per year at the community and health centre level between the two study arms |
We will calculate the number of curative consultations per year at the community and health centre level over the 36-month trial period. |
36 months |
|
Secondary |
Difference in the percentage pregnant women completing four or more prenatal consultations between the two study arms |
We will calculate the pregnant women completing four or more prenatal consultations over the 36-month trial period. |
36 months |
|
Secondary |
Difference in the average gestational age at first prenatal consultation between the two study arms |
We will calculate the average gestational age at first prenatal consultation over the 36-month trial period. Alternatively, we will consider percentage of pregnant women with first prenatal consultation in the first trimester over the 36-month trial period. |
36 months |
|
Secondary |
Difference in the percentage of participants using modern method of a family planning between the two study arms |
We will calculate the percentage of participants using a modern method of family planning over the 36-month trial period. |
36 months |
|